US 11,865,195 B2
Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
Albert J. Sinusas, Guilford, CT (US); Joseph G. Akar, New Haven, CT (US); Richard R. Cesati, Pepperell, MA (US); Heike S. Radeke, South Grafton, MA (US); and Stephen B. Haber, Westford, MA (US)
Assigned to Lantheus Medical Imaging, Inc., North Billerica, MA (US)
Filed by Lantheus Medical Imaging, Inc., North Billerica, MA (US); and Yale University, New Haven, CT (US)
Filed on May 22, 2020, as Appl. No. 16/881,182.
Application 16/881,182 is a continuation of application No. 15/722,958, filed on Oct. 2, 2017, abandoned.
Application 15/722,958 is a continuation of application No. 14/357,555, abandoned, previously published as PCT/US2012/062863, filed on Oct. 31, 2012.
Claims priority of provisional application 61/658,531, filed on Jun. 12, 2012.
Claims priority of provisional application 61/559,587, filed on Nov. 14, 2011.
Claims priority of provisional application 61/558,677, filed on Nov. 11, 2011.
Prior Publication US 2020/0390912 A1, Dec. 17, 2020
Int. Cl. A61K 51/04 (2006.01); A61K 51/08 (2006.01)
CPC A61K 51/044 (2013.01) [A61K 51/0459 (2013.01); A61K 51/0476 (2013.01); A61K 51/0478 (2013.01); A61K 51/0497 (2013.01); A61K 51/08 (2013.01); A61B 2576/023 (2013.01)] 16 Claims
 
1. A method of evaluating risk of developing atrial fibrillation as a primary event comprising:
administering, to a subject, imaging agent 99mTc-RP805:

OG Complex Work Unit Chemistry
wherein TPPTS is 3,3′,3″-phosphanetriyltris(benzenesulfonic acid) trisodium salt, and
acquiring an image of the atria or the aortic valve region of the subject,
wherein the image indicates an aggregate level of MMP comprising MMP-2, MMP-9 and MMP-14 in the atria or the aortic valve region of the subject, and
wherein an aggregate level of MMP in the atria or the aortic valve region of the subject above control is indicative of an increased risk of developing atrial fibrillation.